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Biotechnology is expected to change production methods, the products 
themselves and the structure of the industries in the new economies. 
Hopefully, countries in the Middle-East, Latin America, Asia and Africa 
have already recognized the importance of biotechnology’s promise. In 
this sense, the importance of externalities which might affect the 
success or failure of these companies becomes an issue of paramount 
importance. In the present study, we will try to identify the main external 
factors which could lead in the success of biotechnology firms in Iran. 
To do so, the research follows a qualitative research design to answer 
this main question. Based on our findings, critical success factors are 
categorized in the following categories: General Environment (GE), 
Political Position (PP), Economic Position (EP), and Market Position 
(MP).   
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1. INTRODUCTION 
 Despite high interest in developing the biotechnology industry as the growth 
engine of the future national economy in developed and developing countries, few 
empirical studies have been used to scrutinize critical success factors in the 
biotechnology sector in countries with industry in early development stages. In this 
study, we review the relevant literature, and start our investigation from a developing 
country of interest, i.e. Iran. But, to investigate the topic in a better manner, we 
should firstly define biotechnology. Biotechnology was defined in 1919 by Karl 
Ereky1, in order to describe methods and techniques which produce substances from 
row materials with the aid of living organisms (FÁRI AND; KRALOVÁNSZKY, 2006).  
 A standard definition of biotechnology was proposed and agreed upon in the 
Convention on Biological Diversity in 1992, which argues: "any technological 
application that uses biological systems, living organisms or derivatives thereof, to 
make or modify products and processes for specific use" (YOUNG, 1986). This 
definition was agreed by 168 member nations, and accepted by the Food and 
Agriculture Organization of the United Nations (FAO) and the World Health 
Organization (WHO) as well (MAHBOUDI et al, 2012).  
 Keeping pace with the growing importance of biotechnology and its potential to 
address some of our urgent needs such as those in food and health care industries, 
a spurious and somewhat bogus debate on biotechnology business has been started 
in Iran. The last decade has also seen a significant growth in importance of 
biotechnology firms in numbers of establishments and also in employment. This 
research concentrates on identification of external success factors in biotechnology 
business in Iran. Then, the main question is: "what are the critical external success 
factors of biotechnology firms in Iran?" In order to answer this research question, we 
follow a qualitative approach which includes interview sessions. In order to do so, 
first of all we review the theoretical background of this area and then we will discuss 




                                                 
1 a Hungarian engineer 
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2. LITERATURE REVIEW 
 Today, the pharmaceuticals, biotechnology, medical devices, and diagnostics 
form the backbone of a growing and rapidly integrating life science industry complex 
(LSIC) estimated to be worth a trillion dollars in sales. There is every indication that 
the importance of this set of science based industries will grow very significantly in 
the future. Indeed a number of prestigious reports speak of the emergence of a bio-
economy by 2020 or 2030 (MROCZKOWSKI, 2010). In recent decades, Iranian 
policymakers tried to facilitate the infrastructure movement in the area of 
biotechnology. In 2004, a long-term plan for the national biotechnology policy was 
prepared in which different aspects of biotechnology have been defined in terms of 
education, research, production, and international relations. In recent times, the 
Ministry of Health and Medical Education has allocated a considerable grant 
especially for biotechnology in all Iranian universities. This special grant reveals the 
great importance of biotechnology in the current 5-year plan of national development. 
It should be noted that the research activity and importance of biotechnology had a 
strong impact on the progress of this field in the country. A recent trend toward the 
export of biotechnology products manufactured by private companies has started. It 
is noteworthy that some Iranian biotech products have been exported to Europe, 
South America, India, Egypt and Pakistan (MAHBOUDI, 2005; LARIJANI; ZAHEDI, 
2007; JOSHI, 2013).  
 Critical success factors have been defined as “those few critical areas where 
things must go right for the business to flourish” (ROCKHART, 1979). Critical 
success factors are particularly useful to practitioners as they provide clear guidance 
on where to focus attention (SHANKS et al, 2000). Critical success factors and 
performance indicators provide the biotechnology industry with a foundation on which 
to grow and manage risks. There is a huge demand in the industry to define the 
success factors that dictate what makes a company successful. This need is driven 
by the reality that in order to attract capital to promote industry growth, investors 
require predictable indices (VANDERBYL; KOBELAK, 2007).   
 New biotechnology firms often set up in regions that have innovative firms, 
government laboratories and universities, which attract them to enter (NIOSI; BAS, 
2001). A number of emerging economies increasingly expend resources to improve 
national innovative capabilities and create knowledge economies through the 
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development of biotechnology industries. Standard measures and ways of tracking 
biotechnology industry progress, such as those used by the OECD, were designed 
for developed economies (MROCZKOWSKI; ELMS, 2009).  
 In future, biotechnology will become an even more global industry and new 
entrants from emerging economies will continue to make efforts to become players. 
Emerging market governments and private sector leaders are aware of the strategic 
importance of the bioeconomy for the future and of the opportunities that the rapid 
international outsourcing of R & D may bring. A number of emerging economy 
governments have launched national "catch up" policies of rapid  biotechnology 
development, including Singapore, Taiwan, Brazil, and South Korea 
(MROCZKOWSKI; ELMS, 2009). Iranian government also launched a variety of 
policies to develop biotechnology industry. The main institutes involved in the 
biotechnology sector of the country are as follows:  
 National Institute for Genetic Engineering and Biotechnology,  
 Pasteur Institute of Iran,  
 Razi Institute for Vaccine development,  
 Universities (Sharif University, Tarbiat Modares University, Tehran University 
of Medical Sciences, Mashhad University of Medical Sciences, Gorgan 
University of Medical Sciences, Zanjan University of Medical Sciences, 
Hamadan University of Medical Sciences, Shiraz University of Medical 
Sciences, Semnan University of Medical Sciences, Tehran University, Tabriz 
University of Medical Sciences, Shahid Beheshti University of Medical 
Sciences, and Islamic Azad University),  
 Persian Golf Biotechnology Research center,  
 Agriculture Biotechnology Research Center,  
 Royan Research Centers, and  
 Avacinna Research Centers.  
 The principal policies in biotechnology sector of the country include: National 
Biotechnology Committee at Ministry of Science, Research and Technology; National 
Strategic plan of Biotechnology; Biotechnology Committees at Ministry of Industry 
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and Mine, Ministry of Health, Ministry of Agricultural jihad, Department of 
Environment protection. Moreover, the main priorities of Iranian biotechnology sector 
are:   
 Molecular detection of infectious and genetic diseases  
 Production of Recombinant medicines and vaccines  
 Bioremediation  
 Bioinformatics, Bisafety and Bioethics  
 Transgenic plants Resistance to Biotic and Abiotic Stress  
 Human Genome Diversity  
 Bioleaching of Cooper  
 Oil desulphurization  
 Privatization of Biotechnology Industry  
 The advancement of  biotechnology as a successful industry, confronts many 
challenges related to research and development, creation of investment capital, 
technology transfer and technology absorption, patentability and intellectual property, 
affordability in pricing, regulatory issues and public confidence (MAHBOUDI et al, 
2012). Based on the scientific research and reports, biotechnology techniques can 
solve several potential problems. But what is the opinion of ordinary people about 
these types of changes? Just a decade ago, the awareness of biotechnology was 
very low in most countries. For example, surveys indicated that only about one-third 
of consumers in the USA have heard or read much about biotechnology. In 1995, 
similar results obtained from Japan, France and UK (Hoban, 1997). Although during 
recent years, increased media coverage led to a significant increase in public 
awareness but not public knowledge (SHEIKHHA et al., 2006)   
 In sum, an entrepreneur planning to establish a biotechnology firm in Iran has 
to overcome a lot of different barriers. Partly, those are typical bureaucratic barriers 
making entrepreneurship difficult in general. However, there are also specific barriers 
related to spin-offs initiatives. On top of that there are special difficulties specific to 
the sector of biotechnology. Therefore, in this paper, we reviewed the literature and 
tried to identify the external critical success factors for biotechnology business in Iran.   
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3. METHODOLOGY  
 The multiple case study research approach is used in this research. Case 
studies are used to study phenomena within their real world context (YIN, 1989), and 
may be used to build theory as well (EISENHARDT, 1989). In this study, a process 
model and a set of critical success factors were synthesized from the literature and 
provided a framework based on which interview protocols were developed and the 
multiple case study data is presented. The unit of analysis in the study is the 
management teams of the firms of our study. Multiple case study data was collected 
by two researchers, using interviews of approximately one and a half hours duration 
and based on the same interview protocol. Interviews were conducted with several 
different stakeholders within each of the companies. Other data was collected from 
project documentation and other company literature (DARKE, 1998). Data were 
collected in 2011-2012, based on the interviews from managing boards of 30 
biotechnology firms in Iran.   
4. RESULTS 
4.1 General Environment (GE)  
 Here, general environment is defined as "environment which parameters are 
relevant to all systems or organizations" (CVILIKAS et al, 2007; SALAMZADEH et al., 
2011). More specifically, by general environment we mean those elements which are 
peripheral to biotechnology firms, and are not included in other three categories. The 
main elements are as follows:  
 Motivating environment:   
 Motivating environment is of crucial importance in the success of 
biotechnology firms. The purpose of a motivating environment is to encourage every 
member of a biotechnology firm to motivate himself/herself to contribute his best 
effort to the job at all times (KAMERY, 2004). Based on our findings, a motivating 
environment is a critical success factor for biotechnology firms, as it helps these firms 
in handling their activities and paves the way for their success.   
 Culture:  
 Culture is regarded as an emancipating way of approaching organizational 
phenomena, and as a metaphor for revitalizing organizational theory. Culture 
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consists of the patterns of meanings that link these manifestations together, 
sometimes in harmony, sometimes in bitter conflicts between groups, and sometimes 
in webs of ambiguity, paradox, and contradiction (MARTIN, 1992; SOOREH et al., 
2011). An appropriate culture will make biotechnology firms more able to succeed in 
running their business. In contrast, an inappropriate culture might lead in the failure 
of biotechnology firms.   
 Role models:   
 A role model is someone whose values, attributes, or accomplishments are 
admired, but the role but the role model may have no personal connection to his or 
her admirer (BECK; LAUDICINA, 2001). Role models can still be an effective means 
of imparting professional values, attitudes, and behaviors in biotechnology firms. 
These individuals could pave the way for the success of biotechnology firms as they 
are considered as the unwritten rules of the game.  
4.2 Political Position (PP):   
 The political position is defined by the general legislative system of the society 
and designed legal considerations (SVENSSON, 1986). By political position, one 
might determine the ease of performance by biotechnology firms. Among these 
elements, the followings are of paramount importance for biotechnology firms.  
 Rules and regulations:   
 Rules and regulations governing access and exchange of human biological 
samples are complex and depend upon the nature of the material, national 
legislation, the position of the countries, etc. (REYMOND, 2002; FARSI et al., 2013). 
Motivating rules and regulations could lead in a clear regulatory system which is a 
fertile ground to improve biotechnology business. Also, these could hamper the fluent 
and fluid activity of biotechnology firms.   
 General support:   
 Products of biotechnology research may not be predicted and broad general 
support is needed (GREIF; MERZ, 2007). Otherwise, if general support is not 
available, the success of biotechnology firms might be unclear. General support is a 
vital factor in the success of biotechnology firms, as it could increase or decrease the 
degree of success for biotechnology firms.  
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 Political stability:  
 Political stability and the certainty and enforceability of property rights are two 
important issues for biotechnology firms (PERSAUD, 2001). In more stable countries, 
biotechnology firms could act more freely, while in less stable countries, the success 
of biotechnology firms is a function of bans, embargos, freedom, etc.   
4.3 Economic Position (EP):  
 The economic position is defined by the general economic system of the 
society and economic realities, which can be improved by reducing disposal and 
liability costs, conserving resources, and improving an organization's public image 
(CARTER et al, 2000). Among these elements, the followings are considered as the 
most important ones:  
 Liquidity:   
 The shareholdings of biotechnology firms are mainly composed of persons 
involved in biotechnology. The liquidity of such firms, when they are listed, may be 
reduced compared to other sectors that are easier to understand for a large public of 
investors (MANGEMATIN et al, 2003; LEVITAS; MCFADYEN, 2009).   
 FDI:   
 Although foreign direct investment (FDI) cannot be regarded as a substitute for 
domestic capital, there is growing evidence that the firm can grow by tapping foreign 
investors (MALO; NORUS, 2009). These FDIs could lead in more improvements in 
both technology and techniques. As biotechnology is a high-tech industry, it highly 
relies on investments. This investment could be domestic or kind of FDI. In both 
cases, the investment will grow the pace of technology improvement and guarantee 
the success of biotechnology firms.   
 Investment:  
 In the early stages of development, biotechnology firms miss no opportunity to 
signal the abilities of their scientists as well as the science they are undertaking. 
Especially, the scientists can also serve as bait to the investment community 
(AUDRETSCH; STEPHAN, 1996; TANHA et al., 2011). Growth of biotechnology is a 
function of investment in these firms.  
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4.4 Market Position (MP):  
 The market position is defined by the market success and the strength of the 
market position in comparison to the competition (LECHLER, 2001). To some 
scholars market position is defined in terms of one firm's share of the total market 
and its relation to competitors in the industry (STEVENS et al, 1998). In this research, 
the following elements are the most important ones for biotechnology firms:   
 Marketing and sales:  
 The commercialization of biotechnology is characterized by extensive 
cooperative arrangements. In comparison with not-fully integrated firms, the 
transaction value decreases if the fully integrated licensor has their own marketing 
and sales activities (KOLLMER; DOWLING, 2004).   
 Rivalry:  
 Seemingly, product competition in biotech involves less rivalry (Powell, 1996), 
and more specialization. But, in these industries, the competitive landscape and the 
rules of competitive rivalry change constantly (GEORGE et al, 2002).  
 The following framework illustrates the external critical success factors for 
biotechnology firms.   
Figure 1: External Critical Success Factors in Biotechnology Firms 
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 The development of biotechnology is making rapid progress and the 
importance of biotechnology is growing. Nowadays, both developed and developing 
countries are competing in becoming pioneers in new areas of biotechnology. 
Therefore, gaining knowledge about the critical success factors is becoming of 
paramount importance in this domain. In this paper, we concentrated on Iranian 
biotechnology firms and investigated their success factors. But, a different point of 
view in this research deals with external factors which could be considered as the 
main institutional elements. Based on the findings, critical success factors are 
categorized in the following categories: General Environment (GE), Political Position 
(PP), Economic Position (EP), and Market Position (MP). General Environment (GE) 
is defined as "environment which parameters are relevant to all systems or 
organizations" (CVILIKAS et al, 2007) which includes: Motivating environment, 
Culture, and Role models. Political Position (PP) is defined by the general legislative 
system of the society and designed legal considerations (SVENSSON, 1986), and 
include: Rules and regulations, General support, and Political stability.  Economic 
Position (EP) is defined by the general economic system of the society and economic 
realities, which can be improved by reducing disposal and liability costs, conserving 
resources, and improving an organization's public image (CARTER et al, 2000), and 
includes: Liquidity, FDI, and Investment. Market Position (MP) is defined by the 
market success and the strength of the market position in comparison to the 
competition (LECHLER, 2001), which includes: Marketing and sales, and Rivalry.  
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